Aug 9 2012
Tegal Corporation (NASDAQ: TGAL) today announced that its recently
acquired CollabRx, Inc., subsidiary signed an exclusive license
agreement to provide a version of its proprietary Therapy Finder™ tool
to MedPage
Today, Everyday Health, Inc.'s rapidly growing online site that
serves 96% of all oncologists and 1.6 million monthly online unique
users.
CollabRx is a cloud-based genomic information company that enables
physicians to take into account a tumor's genetic profile when
considering targeted therapies in patient-specific cancer treatments. To
be launched today exclusively at www.MedPageToday.com/Oncology-Next
as "Oncology Next", the CollabRx tool leverages recent years'
dramatic increase in tumor genetic data, which in turn has resulted in a
parallel increase in the development of cancer therapies that target
specific genetic profiles.
CollabRx has developed clinical advisory networks, expert systems,
proprietary tools and processes, and a pipeline of commercial data
products and applications ("apps"). CollabRx Therapy Finders™ are
web-based apps that serve as one type of user interface to access
proprietary CollabRx content, which is dynamically updated and organized
in a knowledgebase that includes information on molecular diagnostics,
medical tests, clinical trials, drugs, biologics and other information
relevant for cancer treatment planning. CollabRx content is supported by
a network of over 50 of the top clinical practitioners in the United
States.
"Oncology Next" will bring CollabRx proprietary content to
registered physicians of MedPage Today, which attracted over 1.6
million unique visitors in June 2012 (comScore), making it one of the
top healthcare professional websites in the U.S. "Oncology Next"
will be available initially as a free digital decision-support service
focusing on treatment of lung cancer. Subsequently on a rolling basis, "Oncology
Next" is to deliver information on treatment of melanoma, colorectal
cancer and breast cancer.
"Oncology Next" is a free service to help physicians choose well
for their patients. Everyday Health and MedPage Today will offer
sponsorships and lead generation tools to major healthcare companies in
connection with this initiative. In addition to licence fees, a portion
of the revenue generated by sponsorships is to be shared with CollabRx.
"The medical doctors and scientists at CollabRx have created this
breakthrough tool, and MedPage Today has the strongest platform
to reach physicians and help change cancer patient outcomes," said James
Karis, CEO of CollabRx, Inc. and Co-CEO of Tegal Corporation.
"The CollabRx strategy is to develop partnerships with key players that
have the greatest reach to multiple health care market segments. We are
excited to be able to announce our first partnership with the leading
digital resource for healthcare professionals."
"MedPage Today's partnership with CollabRx illustrates our
commitment to providing innovative and state-of-the-art tools for
physicians," explained Ben
Wolin, CEO and Co-Founder Everyday Health, Inc. "'Oncology Next'
provides the community of oncologists free access to medical and
scientific advances in genomic medicine to better inform their treatment
planning for their patients."
Early genomic profiling improves cancer treatment outcomes